MOCA Pty Ltd New Zealand is working with the New Zealand Government to establish a medical cannabis research facility.
On December 11, 2018, the New Zealand Government approved a law that will make medical marijuana widely available for thousands of patients over time.
MOCA Pty Ltd New Zealand - Leading the way through research
MOCA Pty Ltd (New Zealand) is working with the New Zealand Government to establish a medical cannabis research facility and in December 2018 submitted a detailed application to the New Zealand Government to cultivate cannabis for medical research as a gateway to obtaining a cultivation licence for production.
In March 2019, the New Zealand government awarded MOCA Pty Ltd (New Zealand) conditional approval for the research licence to cultivate cannabis. The approved research project is on Quality and Safety with a Research Focus on ‘Chemical evaluation of an upcoming cannabis-based medicine, based on organic aquaponics cultivation’.
The approval is subject to establishing a physical facility that meets the security requirements submitted in MOCA Pty Ltd (New Zealand) application. The Company has submitted proprietary architectural plans for the facility with cannabis cultivation design.
MOCA Pty Ltd New Zealand is establishing a high THC organic production facility in New Zealand designed for medical and recreational markets as they appear.
New Zealand cannabis industry.
MOCA Pty Ltd (New Zealand) will continue to work with MedSafe and the NZ Government to finalize its research and cultivation licence. We focus our attention on only THC rich cultivation and manufacture of products in the NZ facility. The facility has scalability as a core and is designed for rapid expansion and will be developed in stages.
The Company submitted to MedSafe NZ, a world class research project along with full operational protocols for security and cultivation. Our propriety protocol developed to meet all cultivation standards. MedSafe has approved the research program subject to the company physically meeting all the security criteria in the facility. The MOCA team will commence operations in New Zealand in late 2020.
Why is cannabis now a medication? To best understand this, one must first understand the importance of the Endocannabinoid System (ECS) that is in the human body. This is a good place to start in the understanding of cannabinoid based medications.
Development of New Zealand Facility
MOCA Pty Ltd (New Zealand) has a staged approach to New Zealand cultivation and the development is in stages.
In Stage 1, we will establish a secure facility for importation and subsequently cultivation. We will develop strong brand presences in New Zealand by importing MOCA branded organic medicinal products from manufactured CBD hemp.
In Stage 2, our secure facility will implement two individual growing rooms, with separate HVAC functionality. The cultivation grow rooms will be capable of producing 2,100kgs of organic cannabis flowers annually. Our current conditionally approved application encompasses all the necessary Standard Operating Procedures to run a medical facility. The SOP’s are proprietary information created for MOCA by international cannabis cultivation consultants.
The cultivation facility maximizes air temperature, humidity, and artificial lighting and provides a high bio-security level barrier to prevent cross-contamination of crops.